Avsnitt
-
8 This week, Jonathan is joined by Chris McIntosh, to discuss the advancement of AI from "bench-to-bedside”, while considering concerns around bias and fairness when working with diverse patient populations.
Use the following timesamps to navigate the episode:
(00:00)-Introduction
(02:28)-An early interest in computer science
(04:13)-Clinical collaborations
(07:46)-AI from “bench to bedside”
(10:08)-Transfer and meta-learning
(12:20)-Transparency in AI
(16:32)-Commercialising radiation therapy
(18:40)-AI revolutionising oncology
(20:49)-Treating cardiovascular disease
(25:45)-Bias in AI datasets
(31:47)-The future of AI
(35:00)-Chris’ three wishes for healthcare
-
This week Jonathan is joined by Joshua Zeidner, Associate Professor of Medicine, University of North Carolina School of Medicine, USA. Together, they discuss findings from recent research and treatment options for acute myeloid leukaemia and myelodysplastic syndrome.
Timestamps:
(00:00)- Introduction
(01:57)- Joshua’s love for the New York Giants
(04:28)- Treatment outcomes in IDH1 and IDH2-mutated acute myeloid leukaemia (AML)
(08:05)- Safety and efficacy of new agents in AML
(17:00)- Treatments for patients with AML with a TP53 mutation
(22:02)- Reliance on transfusion in myelodysplastic syndrome (MDS)
(25:44)- The time from research lab to bedside in drugs to treat AML and MDS
(30:50)- Joshua’s three wishes for healthcare
(35:13)- Outro
-
Saknas det avsnitt?
-
This content has been funded by medac.
In this new insightful podcast, expert in oncological urology Fred Witjes, Radboud University, Nijmegen, the Netherlands, sits down to discuss management of the side effects that follow Bacillus Calmette-Guérin (BCG). Witjes dives into the absolute and relative contraindications for BCG installation, and explores some of the real-world reasons for BCG treatment discontinuation, before delving into what the signs that clinicians should look out for in their patients, and the procedures they can follow to reduce adverse events after BCG. Other topics discussed include: Reducing the rate of lower urinary tract symptoms-related BCG treatment discontinuation; How to increase the confidence of urologists regarding BCG side effect management; How to make adequate use of the major drug classes used in the management of BCG side effects; and When healthcare professionals should make the call to switch treatments. Speakers: Fred Witjes, Radboud University, Nijmegen, the Netherlands -
8. This week, Jonathan is joined by Silvia Munoz-Price, Infectious Diseases Physician; Hospital Epidemiologist; and former Chief Quality & Safety Officer, Virginia Commonwealth University Health, USA. The pair discuss lessons from the COVID-19 pandemic, vaccine hesitancy, and health equity.
Use the following timestamps to navigate this episode:
(00:09)-Introduction
(02:46)-Hospital Consolidations
(08:20)-Reducing safety events
(10:12)-Spotting trends in quality metrics
(15:10)-Vaccine hesitancy
(19:44)-Preparedness ahead of COVID-19
(23:36)-How can we encourage vaccination
(24:41)-The American healthcare system
(31:00)-Removing politics from medicine
(40:27)-Zoonoses and changing migration patterns
(43:59)-Encouraging a career in epidemiology
(45:07)-Silvia’s three wishes -
This week, Jonathan Sackier is joined by Sarah Blagden, a pioneer of experimental oncology research, and CEO of RNA Guardian Ltd, a biotechnology company dedicated to identifying early cancer biomarkers.
Timestamps:
(00:00)-Introduction
(01:30)-Recent reads and tweets
(04:57)-Tweets and cancer acceptance
(07:36)-Sarah's journey into oncology
(09:33)-Exploring new drugs and trials
(11:48)-Global experiences and improving the clinical trial environment
(14:28)-Genetics, research, and oncology
(17:27)-Dysregulation of mRNA translation cancer
(18:36)-The future of prevention
(22:33)-Use of metformin
(26:36)-Join us for more next time!
-
This week, Jonathan Sackier is joined by Carlos Caldas, a world-leading expert in breast cancer research and clinician scientist at the University of Cambridge. Together, they explore how genomic-based classifications of breast cancer are transforming treatment strategies and improving patient outcomes.
Timestamps:
(00:00) – Introduction(02:00) – Carlos’s favourite cuisine
(03:32) – Carlos’s journey into oncology
(08:30) – The redefinition of breast cancer
(14:30) – How this taxonomy influences clinical care
(20:15) - Patient-derived xenografts for breast cancer
(28:00) - Circulating plasma cell-free tumour DNA as a marker of tumour burden
(33:00) – Patient derived tumour cells for drug screening
(35:00) – Vitamin B5 and environmental factors in oncology
(38:44) – Current developments in breast cancer aetiology, diagnosis or treatment
(44:00) – The three wishes for the future of healthcare
(45:00) – Outro
-
This week Jonathan is joined by Isabelle Amigues, CEO and Founder of UnabridgedMD, Denver, Colorado, USA. Together, they discuss the first part of her career as an academic clinician followed by how her diagnosis of Stage IV breast cancer shaped her approach to use the best in data-driven Western medicine combined with traditional Eastern healing.
Timestamps:
(00:00) - Introduction
(02:02) - Isabelle’s unique hobby: rock climbing
(03:33) - Isabelle’s journey into rheumatology
(05:58) - Being diagnosed with Stage IV breast cancer
(14:17) - The mind-body connection
(20:25) - “Hope driven by science”
(24:25) - The benefits of holistic approaches
(32:29) - Psychological distress in healthcare professionals
(37:10) - Synovial fluid and biomarker proteins
(39:48) - Isabelle’s three wishes for healthcare
(42:37) - Outro
-
In this episode of Hema Now, Dr. Jonathan Sackier welcomes Professor Antonio Almeida, a leader in hematology and the 2024 President of the EHA. They delve into the highlights from this year’s EHA Congress, discuss the founding of the Católica Medical School, and explore the transformative role of AI in healthcare.
Timestamps:
(00:00) -Introduction
(01:40) -Reflection on the EHA 2024 Congress
(06:10) -Approaches for future congresses
(10:30) -Proudest accomplishments and EHA education initiatives
(17:00) -Reflections on the treatment landscape of blood-related conditions
(26:00) -Importance of registries in uncovering more about these diseases
(30:10) -Potential of AI in hematology
(32:50) -Role of public policy in shaping the future of hematology
(37:00) -What drove Antonio to found a medical school
(40:00) -Antonio’s three wishes
-
This week, Jonathan Sackier is joined by Prof. Carlos Caldas, a world-leading expert in breast cancer research and clinician scientist at the University of Cambridge. Together, they explore how genomic-based classifications of breast cancer are transforming treatment strategies and improving patient outcomes.
Timestamps:
(00:00) – Introduction
(02:00) – Carlos’s favourite cuisine
(03:32) – Carlos’s journey into oncology
(08:30) – The redefinition of breast cancer
(14:30) – How this taxonomy influences clinical care
(20:15) - Patient-derived xenografts for breast cancer
(28:00) - Circulating plasma cell-free tumour DNA as a marker of tumour burden
(33:00) – Patient derived tumour cells for drug screening
(35:00) – Vitamin B5 and environmental factors in oncology
(38:44) – Current developments in breast cancer aetiology, diagnosis or treatment
(44:00) – The three wishes for the future of healthcare
(45:00) – Outro
-
In this episode, Jonathan is joined by John H. Stone, Professor of Medicine at Harvard Medical School and The Edward A. Fox Chair in Medicine at Massachusetts General Hospital. Stone discusses his groundbreaking work in systemic vasculitis, including granulomatosis with polyangiitis and ANCA-associated vasculitis. He also shares insights into the emerging field of IgG4-related disease and the exciting possibility of the first approved therapy for this condition. Alongside, he delves into his efforts to minimise glucocorticoid toxicity and his work through the IgG4ward! Foundation.
Timestamps:
(00:30) – Introduction
(04:00) – Stone’s journey into rheumatology
(07:28) – WEGET trial
(10:30) – Developments in IgG4-related disease and the path to therapy approval
(15:52) – Key advancements in the treatment of granulomatosis with polyangiitis
(18:04) – Glucocorticoid toxicity and the Glucocorticoid Toxicity Index (GTI)
(20:34) – The IgG4ward! Foundation
(23:48) – Two Pearls and a Myth
(26:45) – Stone’s three wishes for rheumatology
-
In this exclusive podcast, experts in the field, Andrew Foy, Penn State Health Milton S. Hershey Medical Center, and Ed Filippone, Sidney Kimmel Medical College of Thomas Jefferson University, both in Pennsylvania, USA, explore the burden of hypertension on patients and give insights into how to best care for these patients.
Topics covered include:
patient difficulties when managing hypertension; blood pressure measurement and monitoring, and how to best support patients through this; hypertension medications and treatment resistance; and navigating conflicting advice and guidelines. -
This week, Jonathan is joined by John ‘Jack’ Cush, Director of Clinical Rheumatology at the Baylor Research Institute, Dallas, Texas, USA. The two doctors explore novel treatment avenues for rheumatic diseases, and discuss the exciting potential of AI and telemedicine.
Please use the following timestamps to navigate this episode:
(00:00)-Introduction
(02:29)-The history of beer and rock’ n roll
(06:10)-Transitioning into digital medical education
(10:21)-Jack’s podcast: RheumNow
(14:30)-Challenges in lupus diagnosis and management
(16:58)-IL-5 inhibitors: novel drugs for allergic vasculitis
(19:22)-How does diet affect inflammation and bone health?
(24:22)-Telemedicine in rheumatology
(29:26)-Lessons in rheumatoid arthritis care
(33:30)-Soaring costs in healthcare
(36:40)-New horizons in rheumatoid arthritis treatment
(41:37)-The future of AI
(43:30)-Jack’s three wishes for rheumatology
-
In this bonus episode, join EMJ host Dr Hannah Moir as she speaks with our two health and wellbeing experts, Dr Sula Windgassen and Kiera McGarrity, who provide their expertise and personal experiences of using intermittent catheters. The experts address the emotional impact of intermittent catheter use and provide solutions and practical tools to support and improve patient wellbeing and advance the standard of care.
This is episode one of a three-part series: Confident Living with Intermittent Catheterisation.
This podcast was initiated and funded by Convatec. The views and opinions expressed in this podcast are those of the individual speakers and do not necessarily reflect those of Convatec or EMJ.
-
In this second instalment Jonathan is joined by Sunil Gupta, Consultant Haematologist and haemato-oncologist based at Lewisham and Greenwich NHS Trust, UK, to delve further into prophylactic anticoagulation in APML patients with COVID-19 and, anthracycline toxicity, and new drug appraisals for NICE.
Timestamps:
(00:00)-Introduction
(00:25)-Prophylactic anticoagulation in patients with APML
(03:26)-Anthracyclin as the cornerstone of chemotherapy
(08:18)-Developing drugs for cancer
(16:52)-New innovations in haematology
(20:00)-Sunil’s three wishes
- Visa fler
